NCT05998005 First Face Training Evaluation in Tribal Communities
| NCT ID | NCT05998005 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cambridge Health Alliance |
| Condition | Mental Health |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-08-30 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2023-08-30 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to evaluate a culturally grounded training curriculum, First Face for Mental Health, in Tribal communities, using a waitlist controlled trial design. This curriculum will train Tribal community members in how to respond to youth and adults experiencing mental health crises and serve as a bridge between these individuals and the help they need. The main questions the study aims to answer are: * Does the training increase mental health knowledge, capacity and ability to respond to mental health situations, perceived competence to respond, and actual responsive actions among trainees? * Does the training decrease mental health stigmatizing attitudes and increase cultural identity among trainees? Participants will complete surveys before and after completing the First Face training, across five time points over the course of two years. Half of the participants will receive the training initially, and half will receive it six months later. Researchers will compare the two groups to examine whether the trainees demonstrate changes in the outcomes of interest compared to the waitlist control group during the first six months, and whether both groups demonstrate sustained changes after the first six months (i.e., once both groups have received training).
Eligibility Criteria
Inclusion Criteria: * Age 14 or older * Living or working in one of the seven Tribal Nations affiliated with the Healing Lodge of the Seven Nations, including Northwestern United States, including the Coeur d'Alene Tribe, the Confederated Tribes of the Colville Reservation, the Confederated Tribes of the Umatilla Indian Reservation, the Kalispel Tribe of Indians, the Kootenai Tribe of Idaho, the Nez Perce Tribe, and the Spokane Tribe of Indians Exclusion Criteria: * Age 13 or younger * Not living or working in one of the seven Tribal Nations affiliated with the Healing Lodge of the Seven Nations, including Northwestern United States, including the Coeur d'Alene Tribe, the Confederated Tribes of the Colville Reservation, the Confederated Tribes of the Umatilla Indian Reservation, the Kalispel Tribe of Indians, the Kootenai Tribe of Idaho, the Nez Perce Tribe, and the Spokane Tribe of Indians
Contact & Investigator
Sarah E. Nelson, Ph.D.
PRINCIPAL INVESTIGATOR
Cambridge Health Alliance
Frequently Asked Questions
Who can join the NCT05998005 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, studying Mental Health. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05998005 currently recruiting?
Yes, NCT05998005 is actively recruiting participants. Contact the research team at sarah_nelson@hms.harvard.edu for enrollment information.
Where is the NCT05998005 trial being conducted?
This trial is being conducted at Bonners Ferry, United States, Lapwai, United States, Plummer, United States, Malden, United States and 5 additional locations.
Who is sponsoring the NCT05998005 clinical trial?
NCT05998005 is sponsored by Cambridge Health Alliance. The principal investigator is Sarah E. Nelson, Ph.D. at Cambridge Health Alliance. The trial plans to enroll 1,000 participants.